Sandra Levy is Managing Editor-Projects. She covers self care, chains and business, home care, over-the-counter medicines and Rx-to-OTC switches. She joined <i>Drug Topics</i> in 1998.
Is phenylephrine an effective decongestant?
April 2nd 2007A group of researchers at the University of Florida College of Pharmacy recently submitted a citizen's petition asking the Food & Drug Administration to increase the maximum allowable dose of phenylephrine (PE) from 10 mg to 25 mg and to withdraw approval of phenylephrine for children under 12 years of age. The petition also called for additional research to validate the safety and effectiveness of the higher recommended dose.
R.Ph.s speak out about OTC version of orlistat
March 5th 2007Pharmacists appear pleased with the Food & Drug Administration's recent decision to allow orlistat 60-mg capsules to go over the counter (OTC) in the United States. (See Latebreakers, Feb. 19.) The OTC version, to be marketed by GlaxoSmithKline beginning this summer under the brand name alli, is for use by overweight adults 18 years and older in conjunction with a reduced-calorie, low-fat diet.
How will the minimum wage hike affect you?
February 5th 2007The House of Representatives recently passed a measure to increase the federal minimum wage to $7.25 an hour from its current rate of $5.15 an hour over a 26-month period. The Senate is expected to move swiftly to pass a similar measure. How will the hike affect chain and independent pharmacies?
New law requires OTC adverse event reporting
February 5th 2007Congress just passed and President Bush signed the Dietary Supplement and Nonprescription Drug Consumer Protection Act (S. 3546), also known as the Adverse Event Reports (AER) bill. The legislation will amend the federal Food, Drug & Cosmetic Act to require manufacturers to report "serious" adverse events for OTC drugs and dietary supplements to the Food & Drug Administration. The law becomes effective one year after its passage on Dec. 26.
NAMS issues new position statement on calcium
January 22nd 2007Osteoporosis occurs most commonly in postmenopausal women, and the incidence increases with age. This concern has prompted the North American Menopause Society (NAMS) to issue a new evidence-based position statement on the role of calcium in peri- and postmenopausal women.
Physicians-to-be getting trained at Rite Aid stores
January 8th 2007Picture this scenario: Family medicine residents complete a four-week rotation in a pharmacy, where they learn about the importance of collaborating with pharmacists to improve patient care. They also learn about over-the-counter medicines and how to write prescriptions.
Do loyalty programs boost drugstore sales?
December 11th 2006Drugstore customers who are rewards program members are more likely to have spent more money in the past six months than those not involved in a rewards program, according to a new on-line survey conducted by Maritz Research for Maritz Loyalty Marketing.
Will holiday sales be marvelous or middling?
December 11th 2006Rising gasoline prices have drained consumers' wallets this year. The housing market is losing steam. The war in Iraq is dragging on. Still, chains and independents are optimistic that consumers will fill Santa's sleigh with gifts plucked from their shelves. The National Retail Federation's (NRF) annual Holiday Consumer Intentions and Actions Survey offers plenty of reasons for retailers to celebrate.
PPSI to FDA: Regulate acetaminophen labeling
November 20th 2006Pharmacists Planning Service Inc. (PPSI) has submitted a citizen's petition to the Food & Drug Administration to regulate the labeling and packaging of acetaminophen/APAP-containing products so that the label states, "Contains acetaminophen. Do not take with any other acetaminophen/ APAP." PPSI is also asking that no more than 50 tablets be sold in a bottle and that the FDA mandate a MedGuide.
DEA issues rule on pseudoephedrine products
November 6th 2006As the pharmacy community complies with the Drug Enforcement Administration's interim final rule on retail sales of pseudoephedrine-related products, pharmacy and retail associations are preparing to send their comments to the agency outlining their members' concerns.